Compounds / Hormonal / Anastrozole

Anastrozole

Anastrozole (Arimidex — Non-Steroidal Aromatase Inhibitor)
HormonalFDA: FDA-APPROVED (breast cancer in...WADA: PROHIBITED — Category S4

Overview

FDA-approved for breast cancer. Off-label: estrogen management in men on TRT, gynecomastia prevention, hypogonadism. Caution: excessive estrogen suppression in men reduces libido, bone density, cardiovascular markers.

Mechanism of Action

Reversible non-steroidal aromatase (CYP19A1) inhibitor. Blocks conversion of androgens (testosterone, androstenedione) to estrogens (estradiol, estrone). Reduces circulating estradiol by ~85% in postmenopausal women. In men: manages estrogen elevation during TRT, preserves bone density consideration.

Molecular Profile

Molecular weight
293.4 Da
CAS number
120511-73-1

Key Research Findings

CYP19A1 inhibition; 85% E2 reduction; FDA-approved breast cancer; TRT estrogen management off-label; bone density consideration.

Published Research

J Androl (2001)
Taxel P et al. Anastrozole-induced changes in bone turnover and estradiol in older men
View source
Bone (2009)
Burnett-Bowie SA et al. Effects of aromatase inhibition in hypogonadal older men
View source

Related Hormonal Compounds

HCGGonadorelinKisspeptinOxytocinHMGACTH 1-39
Clinical Guidance

Research data is not a treatment plan. If you are considering Anastrozole, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running Anastrozole? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals